First Epoetin Alfa Biosimilar Approved in the US

The first biosimilar erythropoiesis-stimulating agent has received FDA approval for a number of indications. It is expected to be less costly than the patented biologic.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply